Investors Urged to Act Before Deadline in Class Action Against Pacira BioSciences
In a recent announcement, Kahn Swick & Foti, LLC (KSF) has called attention to shareholders of Pacira BioSciences, Inc. who have experienced substantial financial losses. The firm, which is represented by Charles C. Foti, Jr., a former Attorney General of Louisiana, is reminding investors that they only have until March 14, 2025, to submit lead plaintiff applications in an ongoing securities class action lawsuit against Pacira BioSciences (NasdaqGS PCRX). The lawsuit pertains to purchases made within a critical time frame between August 2, 2023, and August 8, 2024.
The lawsuit has been filed in the United States District Court for the District of New Jersey. Shareholders who acquired Pacira's securities during this period are encouraged to act swiftly. Anyone interested in learning more about their legal rights following these developments, and the potential implications for their investment, may contact KSF Managing Partner Lewis Kahn at 1-877-515-1850 or via email at lewis.kahn@ksfcounsel.com. Detailed information on the case can also be accessed through the KSF website at their dedicated case page.
The core allegations against Pacira BioSciences and certain executives involve a failure to disclose crucial information that negatively affected investors during the aforementioned period, in violation of federal securities laws. A notable event was the August 9, 2024, announcement from Pacira regarding its legal battle with eVenus over patent infringements concerning its flagship product, Exparel, which constitutes approximately 80% of the company's revenue.
On this occasion, the U.S. District Court for New Jersey ruled that Pacira’s U.S. Patent No. 11,033,495 was not valid, subsequently indicating that eVenus was not infringing upon it. Following this disclosure, Pacira's stock suffered a dramatic downturn, plummeting by over 47% from $22.36 per share at the close on August 8 to a low of $11.70 just a day later. This sudden drop exemplified the market's stark reaction to the news, raising alarms among investors regarding their potential losses.
The ongoing legal proceeding is officially titled Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322. For those eligible to participate, including public institutional investors and retail shareholders who have sustained significant losses, the opportunity to assert claims as lead plaintiffs is invaluable. It offers a means to recover losses attributed to corporate misconduct or misrepresentation. Kahn Swick & Foti is recognized as a leading boutique law firm specializing in securities litigation, actively pursuing justice for clients against publicly traded companies engaging in fraudulent behavior. The firm boasts offices across various locations in New York, Delaware, California, Louisiana, Chicago, and New Jersey, thus facilitating their reach and impact in securities litigation.
In summary, the deadline for filing lead plaintiff applications regarding this critical class action against Pacira BioSciences is fast approaching. Interested investors are advised to consult with KSF promptly to explore their legal options and safeguard their investment interests. In turbulent times, having knowledgeable legal representation can be crucial for achieving the best possible outcome in matters of securities litigation.
The lawsuit has been filed in the United States District Court for the District of New Jersey. Shareholders who acquired Pacira's securities during this period are encouraged to act swiftly. Anyone interested in learning more about their legal rights following these developments, and the potential implications for their investment, may contact KSF Managing Partner Lewis Kahn at 1-877-515-1850 or via email at lewis.kahn@ksfcounsel.com. Detailed information on the case can also be accessed through the KSF website at their dedicated case page.
The core allegations against Pacira BioSciences and certain executives involve a failure to disclose crucial information that negatively affected investors during the aforementioned period, in violation of federal securities laws. A notable event was the August 9, 2024, announcement from Pacira regarding its legal battle with eVenus over patent infringements concerning its flagship product, Exparel, which constitutes approximately 80% of the company's revenue.
On this occasion, the U.S. District Court for New Jersey ruled that Pacira’s U.S. Patent No. 11,033,495 was not valid, subsequently indicating that eVenus was not infringing upon it. Following this disclosure, Pacira's stock suffered a dramatic downturn, plummeting by over 47% from $22.36 per share at the close on August 8 to a low of $11.70 just a day later. This sudden drop exemplified the market's stark reaction to the news, raising alarms among investors regarding their potential losses.
The ongoing legal proceeding is officially titled Alvarez v. Pacira BioSciences, Inc., et al., No. 25-cv-00322. For those eligible to participate, including public institutional investors and retail shareholders who have sustained significant losses, the opportunity to assert claims as lead plaintiffs is invaluable. It offers a means to recover losses attributed to corporate misconduct or misrepresentation. Kahn Swick & Foti is recognized as a leading boutique law firm specializing in securities litigation, actively pursuing justice for clients against publicly traded companies engaging in fraudulent behavior. The firm boasts offices across various locations in New York, Delaware, California, Louisiana, Chicago, and New Jersey, thus facilitating their reach and impact in securities litigation.
In summary, the deadline for filing lead plaintiff applications regarding this critical class action against Pacira BioSciences is fast approaching. Interested investors are advised to consult with KSF promptly to explore their legal options and safeguard their investment interests. In turbulent times, having knowledgeable legal representation can be crucial for achieving the best possible outcome in matters of securities litigation.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.